Theravance Biopharma Stock Price

-0.20 (-1.52%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Theravance Biopharma Inc TBPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.20 -1.52% 12.96 15:35:03
Open Price Low Price High Price Close Price Prev Close
13.10 12.87 13.43 13.16
Bid Price Ask Price Spread News
12.94 12.97 0.03 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,536 133,271 $ 13.04 $ 1,737,192 - 12.87 - 22.74
Last Trade Time Type Quantity Stock Price Currency
15:35:02 20 $ 12.96 USD


Draw Mode:

Theravance Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 932.85M 71.98M 40.32M $ 71.86M $ - -4.47 -3.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 133.28k 7.60%

more financials information »

Theravance Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TBPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week14.0314.0312.8713.47234,420-1.07-7.63%
1 Month14.4515.0112.8713.80289,290-1.49-10.31%
3 Months19.5819.99512.8716.03364,168-6.62-33.81%
6 Months18.5222.7412.8718.02343,196-5.56-30.02%
1 Year20.0622.7412.8717.88346,020-7.10-35.39%
3 Years23.1635.4812.8721.36309,283-10.20-44.04%
5 Years25.5643.4412.8724.38286,167-12.60-49.3%

Theravance Biopharma Description

Theravance Biopharma is a diversified biotechnology company that creates medicines to treat serious illnesses. The company's research and development are concentrated primarily on four therapeutic areas-infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease. Its commercial infrastructure is focused primarily on the acute care setting. The company uses strategic collaboration with other industry players. Theravance generates the majority of its revenue in the U.S. and Europe, followed by Asia.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.